Richard Holden

Richard Holden
T: +44 (0) 20 7246 0509

Richard is a Partner at Alantra and has been advising entrepreneurs, mid-market corporates and private equity firms on transactions for almost 20 years.

Richard is a key member of the Alantra global Business Services sector group and leads the UK team. He has a particular focus on Professional Services and Consulting, TIC businesses, HR Services and tech-enabled support services.

Recent transactions have included the acquisition of Concept Life Sciences by Spectris plc; the management buy-outs YSCJohn Charcol/Wren Sterling and Efficio; and the sales of Celerant Consulting to Hitachi, Routeco to France's Sonepar, Alcumus to Inflexion Private Equity and its subsequent acquisition of Santia, and the sale of The Automated Technology Group (ATG) to Wood Group plc. 

Richard graduated in French and German from Cambridge University before qualifying as a chartered accountant at RSM Robson Rhodes and working in their London and Paris lead advisory team for eight years. Richard has spent the last 18 years focused on transactions in the mid-market, and has been a member of the Alantra team in the UK since 2006.

He is married and has a young son to keep him busy. He is a keen skier and climber when time permits.


Alantra appoints experienced partner to head up its UK Real Estate & Hospitality team

Alantra has appointed Hoong Wey Woon as a Partner to head up its UK Real Estate & Hospitality team.  

Alantra advises Strong Roots on securing over €15.5m of investment

Alantra advises Strong Roots, one of the UK’s fastest-growing food companies, on securing over €15.5m of investment 

Alantra advises i2S on its sale to Gfi Informatique

Alantra advises Portuguese IT firm, i2S, on its sale to Gfi Informatique 

Alantra expands its technology sector team with two senior appointments

Alantra has expanded its Technology Media and Telecoms (TMT) sector team with two senior appointments. James Chapman-Andrews joins as Partner and Head of UK TMT and Simon Devonshire OBE, joins as Technology Industry Adviser.  

Alantra advises on sale of 3P Biopharmaceuticals to Keensight Capital

We advised Cinfa and the rest of the shareholders on the sale of 3P Biopharmaceuticals to Keensight Capital, a European growth private equity fund with deep expertise in healthcare.